Combination Inhalers for Upper Airway Diseases
|出版商||Greystone Research Associates||商品編碼||337817|
由於可用性，及對許多患者來說上呼吸道疾病相關症狀的管理改善， 組合吸入藥的開發活動及產品普及大幅度增加。組合吸入藥主要以吸入皮質類固醇和支氣管擴張劑的組合構成。這些產品，預測2020年代後半將大幅度增加的2個市場 - 氣喘及慢性阻塞性肺病的市場將取得大幅商業性成功。
本報告提供組合 (並用) 口服吸入藥的市場相關調查、輸送複數藥物的口服吸入器技術、產品的技術課題與發展的市場要素、開發階段的聯合治療吸入藥與市場投入計劃、吸入藥廠商與對其聯盟合作夥伴的經濟、技術、規定要素的影響等相關分析、組合吸入藥的市場資料與預測，及主要企業簡介等彙整，為您概述為以下內容。
Combination inhalers - oral inhalers containing two drugs that complement the therapeutic actions of one another - have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated - Asthma and COPD - both of which are forecast to grow at impressive rates for the remainder of the decade.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
‘The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. The current trend in asthma and COPD inhaler evolution has seen an increase in the incorporation of ergonomic features by device designers aimed at increasing patient receptiveness. Recent inhaler designs have approached the goals of improved usability and patient adherence from a number of distinct directions, including dose preparation technology, dose packaging, novel formulation technology, dosing confirmation, and symptoms monitoring.’
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.